214 related articles for article (PubMed ID: 21791571)
1. Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases.
Kratochwil C; López-Benítez R; Mier W; Haufe S; Isermann B; Kauczor HU; Choyke PL; Haberkorn U; Giesel FL
Endocr Relat Cancer; 2011 Oct; 18(5):595-602. PubMed ID: 21791571
[TBL] [Abstract][Full Text] [Related]
2. Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial 177Lu/90Y-DOTATOC and 213Bi-DOTATOC radiopeptide therapy.
Giesel FL; Wulfert S; Zechmann CM; Haberkorn U; Kratochwil C; Flechsig P; Kuder T; Schwartz LH; Bruchertseifer F
Exp Oncol; 2013 Jun; 35(2):122-6. PubMed ID: 23828389
[TBL] [Abstract][Full Text] [Related]
3. Intraoperative somatostatin receptor detection after peptide receptor radionuclide therapy with (177)Lu- and (90)Y-DOTATOC (tandem PRRNT) in a patient with a metastatic neuroendocrine tumor.
Todorović-Tirnanić M; Kaemmerer D; Prasad V; Hommann M; Baum RP
Recent Results Cancer Res; 2013; 194():487-96. PubMed ID: 22918778
[TBL] [Abstract][Full Text] [Related]
4. Intraindividual comparison of selective arterial versus venous 68Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors.
Kratochwil C; Giesel FL; López-Benítez R; Schimpfky N; Kunze K; Eisenhut M; Kauczor HU; Haberkorn U
Clin Cancer Res; 2010 May; 16(10):2899-905. PubMed ID: 20460485
[TBL] [Abstract][Full Text] [Related]
5. Prospective Within-Patient Assessment of the Impact of an Unlabeled Octreotide Pre-dose on the Biodistribution and Tumor Uptake of
Lodge MA; Solnes LB; Chaudhry MA; Wahl RL
Mol Imaging Biol; 2021 Oct; 23(5):766-774. PubMed ID: 33829361
[TBL] [Abstract][Full Text] [Related]
6. Super-selective hepatic arterial infusions as established technique ('ARETAIEION' Protocol) of [177Lu]DOTA-TATE in inoperable neuroendocrine liver metastases of gastro-entero-pancreatic (GEP) tumors.
Limouris GS; Karfis I; Chatzioannou A; Paphiti MI; Lyra M; Gennatas K; Nikou G; Voros D; Pragulidis GP; Polydorou AA; Gouliamos A
Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):551-8. PubMed ID: 23358409
[TBL] [Abstract][Full Text] [Related]
7. Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor.
Stoeltzing O; Loss M; Huber E; Gross V; Eilles C; Mueller-Brand J; Schlitt HJ
Langenbecks Arch Surg; 2010 Feb; 395(2):185-92. PubMed ID: 19506898
[TBL] [Abstract][Full Text] [Related]
8. Intraarterial Peptide Receptor Radionuclide Therapy Using
Lawhn-Heath C; Fidelman N; Chee B; Jivan S; Armstrong E; Zhang L; Lindsay S; Bergsland EK; Hope TA
J Nucl Med; 2021 Feb; 62(2):221-227. PubMed ID: 32513903
[TBL] [Abstract][Full Text] [Related]
9. Multimodal imaging for early functional response assessment of (90)Y-/ (177)Lu-DOTATOC peptide receptor targeted radiotherapy with DW-MRI and (68)Ga-DOTATOC-PET/CT.
Wulfert S; Kratochwil C; Choyke PL; Afshar-Oromieh A; Mier W; Kauczor HU; Schenk JP; Haberkorn U; Giesel FL
Mol Imaging Biol; 2014 Aug; 16(4):586-94. PubMed ID: 24526358
[TBL] [Abstract][Full Text] [Related]
10. Qualitative and quantitative image analysis of CT and MR imaging in patients with neuroendocrine liver metastases in comparison to (68)Ga-DOTATOC PET.
Flechsig P; Zechmann CM; Schreiweis J; Kratochwil C; Rath D; Schwartz LH; Schlemmer HP; Kauczor HU; Haberkorn U; Giesel FL
Eur J Radiol; 2015 Aug; 84(8):1593-1600. PubMed ID: 25999064
[TBL] [Abstract][Full Text] [Related]
11. [(111)In-DTPA]octreotide tumor uptake in GEPNET liver metastases after intra-arterial administration: an overview of preclinical and clinical observations and implications for tumor radiation dose after peptide radionuclide therapy.
Pool SE; Kam BL; Koning GA; Konijnenberg M; Ten Hagen TL; Breeman WA; Krenning EP; de Jong M; van Eijck CH
Cancer Biother Radiopharm; 2014 May; 29(4):179-87. PubMed ID: 24820805
[TBL] [Abstract][Full Text] [Related]
12. Potential for Increasing Uptake of Radiolabeled
Pollard JH; Menda Y; Zamba KD; Madsen M; O'Dorisio MS; O'Dorisio T; Bushnell D
Cancer Biother Radiopharm; 2021 Oct; 36(8):632-641. PubMed ID: 34252288
[No Abstract] [Full Text] [Related]
13. Effectiveness of radiolabelled somatostatin analogues (
Medina-Ornelas SS; García-Pérez FO
Rev Esp Med Nucl Imagen Mol; 2017; 36(3):166-174. PubMed ID: 27890514
[TBL] [Abstract][Full Text] [Related]
14. Intraarterial treatment of GEP NET: (68)Ga-DOTATOC SUV cannot predict (90)Y-DOTATOC uptake.
Brogsitter C; Faulhaber D; Kotzerke J
Clin Cancer Res; 2011 Apr; 17(7):2065. PubMed ID: 21447724
[No Abstract] [Full Text] [Related]
15. [(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study.
Baum RP; Kluge AW; Kulkarni H; Schorr-Neufing U; Niepsch K; Bitterlich N; van Echteld CJ
Theranostics; 2016; 6(4):501-10. PubMed ID: 26941843
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
[TBL] [Abstract][Full Text] [Related]
17. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
Recent Results Cancer Res; 2013; 194():353-71. PubMed ID: 22918768
[TBL] [Abstract][Full Text] [Related]
18. ²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience.
Kratochwil C; Giesel FL; Bruchertseifer F; Mier W; Apostolidis C; Boll R; Murphy K; Haberkorn U; Morgenstern A
Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2106-19. PubMed ID: 25070685
[TBL] [Abstract][Full Text] [Related]
19. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.
Gabriel M; Oberauer A; Dobrozemsky G; Decristoforo C; Putzer D; Kendler D; Uprimny C; Kovacs P; Bale R; Virgolini IJ
J Nucl Med; 2009 Sep; 50(9):1427-34. PubMed ID: 19690033
[TBL] [Abstract][Full Text] [Related]
20. Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors.
Frilling A; Weber F; Saner F; Bockisch A; Hofmann M; Mueller-Brand J; Broelsch CE
Surgery; 2006 Dec; 140(6):968-76; discussion 976-7. PubMed ID: 17188146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
